Current Trials

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured.

The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours.

Early stage breast cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab.

Ovarian cancer

The purpose of this study is to investigate if two medications; Rucaparib and Nivolumab used together or separately are better than the current best available treatment for patients who have had platinum-based chemotherapy for ovarian cancer.

Previously untreated or unresectable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread.

Patients with complete resection of Stage IIIa/b/c/d or Stage IV Melanoma

The purpose of this trial is to compare whether there is a difference in treatment outcome for patients treated with Nivolumab manufactured by Process C or the newly developed comparable drug manufactured by Process D.

Participants with Chronic Myeloid Leukaemia (CML) and Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) who are being treated with their first or subsequent tyrosine kinase inhibitor (TKI) therapy.

The purpose of this observational study is to evaluate the prevalence of mutations in patients with Chronic Myeloid Leukaemia (CML) who meet the European Leukaemia Net (ELN) criteria for warning or failure and patients with Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) with detectable BCR-ABL currently being treated with first or subsequent Tyrosine Kinase Inhibitor (TKI) therapy in the UK, Ireland, or France using Next-Generation Sequencing.

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.

Patients with cancer admitted at participating sites who test positive for SARS-CoV-2 infection.

This study is being done to collect data regarding the impact of SARS-CoV-2 infection on patients with cancer, and on the functioning and organisation of cancer services in the Republic of Ireland in response to the 2020 SARS-CoV-2 pandemic.

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.

Advanced or Metastatic ER+/HER2- Breast Cancer.

This clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).

Cervical cancer

The purpose of the study is to investigate if Tisotumab Vedotin (HuMax®-TF-ADC) is safe and has an additive effect when used with other anti-cancer medications in the treatment of recurrent or advanced cervical cancer.

Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

The purpose of this trial is to evaluate the efficacy of pemigatinib versus standard chemotherapy in the first-line treatment of patients with Unresectable or Metastatic Cholangiocarcinoma, whos tumors harbor FGFR2 gene rearrangement.